The Directorate General of Royal Hospital has launched the "TruClear™" system for hysteroscopic tissue removal within the hospital's outpatient hysteroscopy service—a step described as a qualitative leap in minimally invasive gynecological surgery services.

The new technology allows female patients to undergo the removal of certain tissues inside the uterus, including small polyps and fibroids, in an outpatient setting using a hysteroscope. This approach can shorten the treatment journey and reduce the need for operating rooms and general anesthesia.

Previously, cases requiring the removal of small polyps or fibroids with a hysteroscope had to be performed using traditional hysteroscopy techniques in operating rooms. This usually required anesthesia and a recovery period before the patient could leave the hospital.

With the new technology, select cases can now benefit from the ability to combine both diagnosis and treatment in a single visit under direct vision. This reduces the need for scheduling, anesthesia, and operating room admission, shortens the patient's hospital stay, and accelerates their return to daily activities.

The "TruClear™" technology is approved for clinical use and holds regulatory accreditation, supported by published scientific evidence. It is used globally for hysteroscopic tissue removal in a wide range of cases, including polyps and selected cases of intrauterine fibroids. Studies have demonstrated its high efficacy and shorter procedure times in some cases compared to traditional techniques, while maintaining safety and quality of care standards. The technology is being implemented in accordance with approved local accreditation and regulatory requirements in the health facility.